If anyone believes that the downsizing of the PMU industry here in North America is advantageous for the mares and foals who suffer at the hands of Big Pharma, they are sadly mistaken”.
Sadly mistaken indeed.
Allin open our eyes further:
While it is true that immediately following the release of the WHI study, citing the horrors associated with CEE-derived HRT, there was a precipitous drop in sales of Premarin® and Prempro®, some of that market was reclaimed in time via reduced dosage recommendations, aggressive marketing strategies, price increases and the wide availability of these drugs without prescriptions through Internet sales.
What no one realized at the time was that Wyeth had probably begun to move their PMU facilities prior to or just after the damning results of the WHI were released to the public.
A simple Internet search shows that several pharmaceutical-based companies in mainland China and India produce bulk conjugated estrogens in powder form. Interestingly enough, or perhaps clearly enough, Wyeth/Pfizer is and has been a customer for several years. Whether their procurements are limited to conjugated estrogens is unknown. But really, who else would purchase these products in such quantities without a vested interest in them?
In fact, according to information we procured from an inside source from one such company, PMU farms have been in operation in Northern China for the last 8 years. The company’s manufacturing site is also in the same general location.
WHAT YOU CAN DO
— Send our Dear Physician Letter to the OB/GYN’s in your area, particularly to the one you are consulting yourself, asking them not to prescribe the Premarin family of drugs. Learn more here >>
— Send our flyer to Pfizer asking them to develop an alternative to the Premarin family of drugs using new technologies that do not involve the use of pregnant mare’s urine. Learn more here >>
— Say no if your doctor tries to prescribe Premarin and Prempro.
— Learn why we must end the use of pregnant mare’s urine in drugs.
Written by JANE ALLIN
Research Analyst | Int’l Fund for Horses
Since the introduction of Premarin in 1942, much controversy has followed the lucrative market monopoly of the world’s first conjugated equine estrogen therapy for the treatment of postmenopausal women.
Historically, the number of PMU farms, sequestered mares and by-product foals steadily rose until the early 1990’s at which time a precipitous increase was observed (Figure 1). The escalation in the number of PMU farms appeared to coincide with the widespread compliance of physicians to prescribe Premarin® based on a powerful sales pitch by Wyeth that gave doctors and women alike the impression that every woman should be treated at menopause for declining estrogen levels and in particular the escalated risk of developing osteoporosis.
This marketing agenda not only falsely concluded that aging and menopause are diseases requiring treatment but also failed to admonish the inherent dangers associated with HRT. As far back as the mid-1970’s there was damaging evidence that the use of HRT was linked to cancer.
Apart from the burgeoning sales of Premarin® and then the inception of Prempro® in 1995, by the early 1990’s there was growing evidence about the risks associated with HRT. Meanwhile the Woman’s Health Initiative (WHI) was launched in 1991 with the objective of conducting medical research about health issues in menopausal women. These clinical randomized controlled trials were designed to test the effectiveness of postmenopausal HRT on heart disease, fractures and breast and colorectal cancer.
Until the time the first results of the WHI study were released in 2001, sales of the Premarin® family of drugs not only flourished but Wyeth gained a further foothold in the control of the marketplace when the FDA rejected an application for a generic brand of its blockbuster drug Premarin®. Both the FDA and Wyeth-Ayerst wanted the public to believe it was in their best interest to protect and safeguard but in reality it was motivated by scores of lobbyists, fraught with conflicts of interest, and epitomized by surreptitious political manipulation.
In fact, in the 1990s Premarin® became the most frequently dispensed drug in the US and by 1997 had become Wyeth-Ayerst’s first brand to reach $1 billion dollars in sales.
By 2001, news of the first results of the WHI hit both physicians and Wall Street alike and Wyeth-Ayerst’s epic family of HRT drugs nosedived in terms of company shares and market value. However, it wasn’t until the US government abruptly ended the WHI in 2002 citing the increased risk of cancers and cardiac complications that sales and use of the drugs by postmenopausal women plummeted.
As clearly illustrated in Figure 1, a steep decline in the number of PMU farms and producing mares was observed shortly after these events in response to the decreased demand of Premarin® and related CEE drugs. Although this may seem to have been a blessing to the suffering mares and their foals, sadly, the vast majority of the mares no longer required to “perform” were sent to slaughter along with their foals whether alive or still in the womb. Albeit lower numbers, the industry still thrives today and the suffering continues.
So where has that left Wyeth, now a subsidiary of Pzifer, the largest drug company in the world?
A closer look at the sales of Premarin® and projected sales of both Premarin® and their soon to be released Aprela conveys a malevolent tale of greed and depravity.
Data taken from a Wyeth Annual Product Sales summary clearly show the drop in profits from Premarin® from 2003 to 2004 that parallels the steep decline in the number of PMU mares as indicated in Figure 1. However, from 2004 and beyond sales increased slightly until 2006 and then remain relatively stable despite the fact that there were further declines in the number of PMU mares over the same period of time. Figure 2 shows the actual and estimated sales from 2003 to 2015 for both Premarin® and Aprela.
What is alarming is that the sales profits appear to be unaffected while at the same time both prescriptions for the Premarin® family of drugs and the number of PMU farms and mares have declined dramatically since 2003 (Figures 3 and 4 respectively).
In fact, there was a decrease of approximately 80% in the number of prescriptions issued by physicians from 2001 to 2008 with a corresponding decrease of about 88% in the number of mares from 2003 to 2007 (estimated from current number of PMU farms and Manitoba/Alberta data). Somewhat confounding may be the prescription data since Premarin® is now available over the Internet without a prescription and so may not reflect the actual demand. However, more importantly, the number of producing mares divulges the underlying ambiguity.
A simple calculation of the profits generated per PMU mare from 2003 to 2007 will shock you (Figure 5).
In 2003, it appears that a single PMU mare generated about 25,000 USD per annum in profits for Wyeth, yet by 2006 and 2007 that same mare was worth in excess of 150,000 USD –- that is a sixfold increase in a mere five years. It is hard to envision a mare ramping up urine and estrogen production to sustain these sales figures.
Instead it is simply a case of Economics 101; Supply and Demand. At least that’s what Wyeth wants the consumer to believe. Unfortunately there is a major flaw in their argument since the overall demand for the Premarin® family of drugs has in fact decreased over time due to the inherent risks of cancer and cardiovascular complications associated with HRT (Figure 3).
While, it is true that the supply of CEEs has decreased, presumably in response to decreased demand, Wyeth has had no other option than to increase the price of its carcinogenic therapies to sustain profit levels.
A CTV news release in June of 2009 documents the scandalous agenda of Big Pharma and its continuing predisposition to gouging the consumer. From April to June of 2009, a month’s supply of Premarin® increased an astonishing 800 per cent, from about 14 cents a pill to about $1.24 a pill. (6)
Unfortunately, when a patent expires there is no limit to what a company can charge for its drugs since its pricing doesn’t come under the jurisdiction of the federal government’s Patented Medicine Review Board (Canada).
Wyeth defends its position with the following gibberish:
The new price is reflective of current costs, including higher manufacturing and ingredient costs and a long-term, steady reduction in the consumption of the product, increasing the per-dose and per-patient cost significantly.”
“Wyeth Pharmaceuticals says its decision “was based on extensive research, including discussions with stakeholders, physicians and patients, and reflects the value Premarin brings to Canadian women. Key inputs from that research showed that Canadian physicians and women wanted us to continue to offer the product.
“While we understand this is undesirable for some patients, the only other option was to remove the product from the market, and many Canadian women continue to rely on this unique product.” (7)
Oh really? As if they would take it off the market. I hardly think so! After all, it is still accruing 1 billion USD a year and with the predicted arrival of Aprela in 2011, which also contains CEEs, Wyeth has estimated that figure to increase even further (Figure 2).
It is simply criminal what Big Pharma is allowed to get away with. Not only is it permissible to manufacture and deceptively market carcinogens, endangering the lives of women and horses alike, it is obviously clear that they can do so at any cost to the consumer. It is no secret that the FDA and the pharmaceutical companies are entwined in a sinister conspiracy, but what about the democratic governments of the United States and Canada?
The pharmaceutical industry is hardly a model of free enterprise. Of course, it is free to manufacture what drugs it sees fit to expand its portfolio of block-busters, many of which are merely slight modifications to existing compounds. It is also free to price them as high as the market will bear. Ultimately however, it is entirely reliant on monopolies delivered to them courtesy of the government, for example patents and FDA endorsed marketing rights.
There has never been a better time to stop this madness.
AN AGREEMENT that will see pharmaceutical giant Pfizer take over rival company Wyeth for $68 billion has caused some uncertainty for pregnant mare’s urine producers in Sask, Man. and in North Dakota.
Norm Luba , executive director of The North American Equine Ranching Information Council (NAERIC) said there are 71 PMU farms in Western Canada and the northern United states — 15 in Saskatchewan, 53 in Manitoba and 3 in North Dakota.
Roughly 5,600 brood mares are involved in PMU production.
Luba said it is too early to assess the impact of the Pfizer-Wyeth takeover, which was announced Jan. 26.
Shane Boyes, a registered Quarter horse-owner and PMU producer in southeastern, Saskatchewan said the impact of the Pfizer agreement is still unknown, but he said Premarin sales have been a significant part of Wyeth’s sales.
“Wyeth has the only natural hormone replacement therapy product,” he said.
“They made a billion dollars from sales of Premarin alone last year. I don’t think Pfizer would dump a billion dollar industry. We will just have to wait and see what happens.”
According to Wyeth, the takeover deal with Pfizer will create one of the most diversified health-care companies in the world.
YOU CAN HELP
Spread the word to the women in your life.
If you are currently seeking Hormone Replacement Therapy, ask your physician to prescribe one of the many safe and effective plant-based alternatives (containing Phytoestrogens) that are available.
For every 150 women who stop taking Premarin, one mare may be spared from the “pee line” and seven or eight “byproduct” foals may not be slaughtered for their meat.